Merck to acquire San Diego biotech company Prometheus Biosciences for $10.8 billion

Under the terms of the deal announced Sunday, Merck (NYSE: MRK) will acquire Prometheus Biosciences (NASDAQ: RXDX) for $200 per share in cash.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.